- Home
- RCEL vs CRVS Comparison
RCEL vs CRVS Comparison
Compare RCEL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- CRVS
- Stock Information
- Founded
- RCEL N/A
- CRVS 2014
- Country
- RCEL United States
- CRVS United States
- Employees
- RCEL N/A
- CRVS N/A
- Industry
- RCEL Medical/Dental Instruments
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- CRVS Health Care
- Exchange
- RCEL Nasdaq
- CRVS Nasdaq
- Market Cap
- RCEL 240.6M
- CRVS 206.5M
- IPO Year
- RCEL N/A
- CRVS 2016
- Fundamental
- Price
- RCEL $6.97
- CRVS $4.43
- Analyst Decision
- RCEL Strong Buy
- CRVS Strong Buy
- Analyst Count
- RCEL 4
- CRVS 3
- Target Price
- RCEL $17.25
- CRVS $16.33
- AVG Volume (30 Days)
- RCEL 197.1K
- CRVS 1.4M
- Earning Date
- RCEL 05-08-2025
- CRVS 05-08-2025
- Dividend Yield
- RCEL N/A
- CRVS N/A
- EPS Growth
- RCEL N/A
- CRVS N/A
- EPS
- RCEL N/A
- CRVS N/A
- Revenue
- RCEL $71,661,000.00
- CRVS N/A
- Revenue This Year
- RCEL $62.33
- CRVS N/A
- Revenue Next Year
- RCEL $30.59
- CRVS N/A
- P/E Ratio
- RCEL N/A
- CRVS N/A
- Revenue Growth
- RCEL 41.35
- CRVS N/A
- 52 Week Low
- RCEL $6.90
- CRVS $1.75
- 52 Week High
- RCEL $14.16
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- RCEL 28.06
- CRVS 68.59
- Support Level
- RCEL $9.50
- CRVS $3.17
- Resistance Level
- RCEL $9.85
- CRVS $3.71
- Average True Range (ATR)
- RCEL 0.53
- CRVS 0.23
- MACD
- RCEL -0.20
- CRVS 0.08
- Stochastic Oscillator
- RCEL 10.03
- CRVS 95.47
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).